Literature DB >> 12065916

Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock.

Edgar Bautista1, F Estelle R Simons, Keith J Simons, Allan B Becker, Krika Duke, Michelle Tillett, Wayne Kepron, Steven N Mink.   

Abstract

BACKGROUND: Epinephrine (Epi) is the treatment of choice for reversing cardiovascular collapse in anaphylactic shock (AS). However, there are few data supporting its use in this condition, and most treatment guidelines have been anecdotally derived. In the present study, the time course of hemodynamic recovery from maximal hypotension was investigated in a canine model of AS in which Epi was administered by the intravenous (IV), subcutaneous (SQ) and intramuscular (IM) routes on different occasions. The findings obtained with Epi treatment were compared to those in a nontreatment study.
METHODS: Ragweed-sensitized dogs were examined in respective studies approximately 5 weeks apart in which Epi was administered by one of the above routes in a randomized design. Either Epi (0.01 mg/kg) or placebo was administered at maximal hypotension, and hemodynamics were followed for 3 h after shock. The animals were studied while ventilated and anesthetized. Mean arterial pressure (MAP), cardiac output, stroke volume (SV), pulmonary wedge pressure (Pwp) and plasma Epi concentrations were obtained at each measurement interval.
RESULTS: In the IV study, Epi produced a transient immediate increase in MAP, SV and Pwp as compared to the nontreatment study (144 vs. 52 mm Hg; 32 vs. 12 ml; 9 vs. 5 mm Hg; p < 0.01), but no differences were observed 15 min after shock. Hemodynamics were not different between Epi and no treatment at any intervals when Epi was given by the SQ and IM routes. AS compared with the placebo study, plasma Epi concentrations were higher in the IV and IM studies, but not in the SQ study.
CONCLUSIONS: Although higher Epi concentrations were observed in the IM and IV studies, a sustained benefit in hemodynamic recovery was not observed in this anesthetized, ventilated canine model. In AS, when administered during maximum shock after mediators have already been released, a single IM, IV or SQ dose of Epi may have limited utility in the treatment of cardiovascular collapse. Earlier administration of Epi, before maximal hypotension occurs, may produce a more beneficial effect. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065916     DOI: 10.1159/000059406

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  9 in total

Review 1.  Food-Induced Anaphylaxis: an Update.

Authors:  Christopher P Parrish; Heidi Kim
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-14       Impact factor: 4.806

2.  Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation.

Authors:  S G A Brown; K E Blackman; V Stenlake; R J Heddle
Journal:  Emerg Med J       Date:  2004-03       Impact factor: 2.740

3.  World allergy organization guidelines for the assessment and management of anaphylaxis.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

Review 4.  Systematic review of outcome measures in trials of pediatric anaphylaxis treatment.

Authors:  Tamar Rubin; Jacqueline Clayton; Denise Adams; Hsing Jou; Sunita Vohra
Journal:  BMC Pediatr       Date:  2014-06-20       Impact factor: 2.125

Review 5.  How to manage anaphylaxis in primary care.

Authors:  Alberto Alvarez-Perea; Luciana Kase Tanno; María L Baeza
Journal:  Clin Transl Allergy       Date:  2017-12-11       Impact factor: 5.871

6.  Limited effect of intramuscular epinephrine on cardiovascular parameters during peanut-induced anaphylaxis: An observational cohort study.

Authors:  Paul J Turner; Monica Ruiz-Garcia; Stephen R Durham; Robert J Boyle
Journal:  J Allergy Clin Immunol Pract       Date:  2020-09-02

7.  A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).

Authors:  Xiaotong Li; Qingbian Ma; Jia Yin; Ya'an Zheng; Rongchang Chen; Yuguo Chen; Tianzuo Li; Yuqin Wang; Kehu Yang; Hongjun Zhang; Yida Tang; Yaolong Chen; Hailong Dong; Qinglong Gu; Daihong Guo; Xuehui Hu; Lixin Xie; Baohua Li; Yuzhen Li; Tongyu Lin; Fang Liu; Zhiqiang Liu; Lanting Lyu; Quanxi Mei; Jie Shao; Huawen Xin; Fan Yang; Hui Yang; Wanhua Yang; Xu Yao; Chunshui Yu; Siyan Zhan; Guoqiang Zhang; Minggui Wang; Zhu Zhu; Baoguo Zhou; Jianqing Gu; Mo Xian; Yuan Lyu; Zhengqian Li; Hangci Zheng; Chang Cui; Shuhua Deng; Chao Huang; Lisha Li; Pengfei Liu; Peng Men; Chunli Shao; Sai Wang; Xiang Ma; Qiang Wang; Suodi Zhai
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

8.  Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization.

Authors:  Stephen F Kemp; Richard F Lockey; F Estelle R Simons
Journal:  World Allergy Organ J       Date:  2008-07       Impact factor: 4.084

9.  Anaphylaxis to three humanized antibodies for severe asthma: a case study.

Authors:  Koichi Jingo; Norihiro Harada; Toshihiko Nishioki; Masahiro Torasawa; Tomoko Yamada; Tetsuhiko Asao; Haruhi Takagi; Tomohito Takeshige; Jun Ito; Kazuhisa Takahashi
Journal:  Allergy Asthma Clin Immunol       Date:  2020-06-10       Impact factor: 3.406

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.